Shares surged 6.4% to $33,100 (LLY.BA) as Eli Lilly detailed exactly how seniors will get its weight-loss drugs for just $50 a month starting July 1 — even as broader U.S. markets drifted lower. The announcement, made June 25, laid out additional details for the Medicare GLP-1 Bridge program taking effect July 1, 2026. The stock has now climbed roughly 12% in just five trading sessions, reflecting Wall Street's conviction that government-backed access to millions of new patients changes the math on Lilly's biggest revenue engine.
Fourteen Million Potential New Customers Walk Through the Door
An estimated 14 million Medicare Part D recipients could obtain these drugs for $50 per month.
Lilly CEO Dave Ricks estimates 20 million to 30 million Medicare beneficiaries suffering from obesity could be eligible, calling coverage a "big multiplier on the eligible pool." Until now, Medicare beneficiaries had to pay out of pocket, costing them potentially hundreds of dollars a month. Removing that barrier is what has investors excited.
A Pill and a Shot Give Lilly Two Bites at Every Patient
Lilly is offering two different medicines: Foundayo, a once-daily oral pill, and Zepbound, the most prescribed injectable weight-management medication. That choice matters because many older patients avoid needles. Citi analysts wrote that broader coverage "further adds to the volume inflection expected from broad Medicare Part D access."
Lower Price, but the Government Picks Up the Tab
The Bridge program operates outside normal Part D coverage — insurers bear no financial risk, and they don't have to opt in. That means the federal government, not insurance plans, absorbs most of the cost. For Lilly, the trade-off is clear: Ricks acknowledged "a step down in pricing" but said volume growth "will ramp on the back half of the year."
In Q1 2026, Lilly's two lead drugs generated over $12.8 billion in combined quarterly sales — any meaningful uptake from Medicare seniors would add materially on top of that base.
The Clock Is Ticking — This Program Expires in 18 Months
The longer-term BALANCE Model that would make Part D plans permanent carriers has been delayed indefinitely, extending the Bridge through December 31, 2027. That gives Lilly an 18-month window to prove the economics work. If government spending data shows GLP-1s reduce hospitalizations and other costs, permanent coverage becomes far likelier. If not, millions of patients could lose access — raising "the possibility that people could gain access… only to lose access to them in 2028."
Leerink raised its price target to $1,232 on June 25 , betting the volume story wins.